Search

Your search keyword '"Seimiya, Hiroyuki"' showing total 435 results
Start Over Author "Seimiya, Hiroyuki"
435 results on '"Seimiya, Hiroyuki"'

1. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells

Author

Chen, Mingjue, Mashima, Tetsuo, Oishi, Taichi, Muramatsu, Yukiko, Seto, Yosuke, Takamatsu, Manabu, Kawata, Naomi, Morino, Shun, Nakamura, Ayane, Inaba, Saori, Yuan, Xunmei, Maruyama, Kohei, Suzuki, Mai, Sato, Ayana, Yoshida, Haruka, Jang, Myung-Kyu, Mizutani, Anna, Takeuchi, Kengo, Yamaguchi, Kensei, Shirai, Fumiyuki, Nagayama, Satoshi, Katayama, Ryohei, and Seimiya, Hiroyuki

Published
2024
Full Text
View/download PDF

3. Pericentromeric noncoding RNA changes DNA binding of CTCF and inflammatory gene expression in senescence and cancer

Author

Miyata, Kenichi, Imai, Yoshinori, Satoshi Hori, Mika Nishio, Loo, Tze Mun, Okada, Ryo, Yang, Liying, Nakadai, Tomoyoshi, Maruyama, Reo, Fujii, Risa, Ueda, Koji, Jiang, Li, Zheng, Hao, Toyokuni, Shinya, Sakata, Toyonori, Shirahige, Katsuhiko, Kojima, Ryosuke, Nakayama, Mizuho, Oshima, Masanobu, Nagayama, Satoshi, Seimiya, Hiroyuki, Hirota, Toru, Saya, Hideyuki, Hara, Eiji, and Takahashi, Akiko

Published
2021

5. Pharmacological targeting of histone H3K27 acetylation/BRD4-dependent induction of ALDH1A3 for early-phase drug tolerance of gastric cancer

Author

Lee, Jin, primary, Mashima, Tetsuo, additional, Kawata, Naomi, additional, Yamamoto, Noriko, additional, Morino, Shun, additional, Inaba, Saori, additional, Nakamura, Ayane, additional, Kumagai, Koshi, additional, Wakatsuki, Takeru, additional, Takeuchi, Kengo, additional, Yamaguchi, Kensei, additional, and Seimiya, Hiroyuki, additional

Published
2024
Full Text
View/download PDF

8. Exploratory Study Identifies Matrix Metalloproteinase-14 and -9 as Potential Biomarkers of Regorafenib Efficacy in Metastatic Colorectal Cancer.

Author

Suenaga, Mitsukuni, Mashima, Tetsuo, Kawata, Naomi, Dan, Shingo, Seimiya, Hiroyuki, and Yamaguchi, Kensei

Subjects
THERAPEUTIC use of antineoplastic agents, PROTEIN kinase inhibitors, PREDICTIVE tests, RESEARCH funding, ENZYME-linked immunosorbent assay, ANTINEOPLASTIC agents, TUMOR markers, COLORECTAL cancer, METASTASIS, TRANSLATIONAL research, CELL lines, GENE expression, MATRIX metalloproteinases, DRUG efficacy, RESEARCH, RESEARCH methodology, PROGRESSION-free survival, DISEASE progression, OVERALL survival, CHEMICAL inhibitors
Abstract

Simple Summary: Regorafenib offers longer survival for patients with refractory metastatic colorectal cancer (mCRC). We aimed to identify biomarkers for regorafenib through preclinical and translational studies. In silico analysis identified matrix metalloproteinase (MMP)-14 and MMP-9 as key biomarkers. Validation in patients receiving regorafenib or FTD/TPI showed that high MMP-14 levels were correlated with a better response to regorafenib. Additionally, lower MMP-9 levels before the second cycle were linked to improved disease control and survival. These findings suggest that MMP-14 and MMP-9 could serve as prognostic markers for regorafenib efficacy. In identifying biomarkers for anticancer drugs, the lack of objectivity in selecting candidate factors makes interpretation difficult. We performed preclinical analysis and a translational validation study to identify candidate biomarkers for regorafenib efficacy in metastatic colorectal cancer (mCRC). Using in silico COMPARE analysis with a human cancer cell line panel, JFCR39, we selected candidate biomarkers whose expression correlates with regorafenib sensitivity. We validated predictive values in mCRC patients receiving regorafenib (discovery, n = 53) and FTD/TPI (control, n = 16). Blood samples were obtained at baseline (BL), before the second cycle (2nd), and at progressive disease (PD), and biomarker levels were measured using ELISA. Our analysis showed that high matrix metalloproteinase (MMP)-14 expression was associated with a high sensitivity to regorafenib. In the discovery cohort, high MMP-14 levels at BL and PD were correlated with tumor shrinkage and longer progression-free survival (PFS). A subsequent analysis of other related factors further indicated that the patients with decreased MMP-9 levels at the 2nd had higher disease control rates, tumor shrinkage, longer PFS, and overall survival than those with increased changes. These findings were not observed in the control cohort. Our study suggests MMP-14 and MMP-9 may serve as prognostic markers for regorafenib and provide insights into novel combination therapies with anti-MMP-9 agents or FTD/TPI. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells

Author

Chen, Mingjue, primary, Mashima, Tetsuo, additional, Oishi, Taichi, additional, Muramatsu, Yukiko, additional, Seto, Yosuke, additional, Takamatsu, Manabu, additional, Kawata, Naomi, additional, Morino, Shun, additional, Nakamura, Ayane, additional, Inaba, Saori, additional, Yuan, Xunmei, additional, Maruyama, Kohei, additional, Suzuki, Mai, additional, Sato, Ayana, additional, Yoshida, Haruka, additional, Jang, Myung-Kyu, additional, Mizutani, Anna, additional, Takeuchi, Kengo, additional, Yamaguchi, Kensei, additional, Shirai, Fumiyuki, additional, Nagayama, Satoshi, additional, Katayama, Ryohei, additional, and Seimiya, Hiroyuki, additional

Published
2023
Full Text
View/download PDF

19. Glutamine deficiency drives transforming growth factor‐β signaling activation that gives rise to myofibroblastic carcinoma‐associated fibroblasts

Author

Mezawa, Yoshihiro, primary, Wang, Tingwei, additional, Daigo, Yataro, additional, Takano, Atsushi, additional, Miyagi, Yohei, additional, Yokose, Tomoyuki, additional, Yamashita, Toshinari, additional, Yang, Liying, additional, Maruyama, Reo, additional, Seimiya, Hiroyuki, additional, and Orimo, Akira, additional

Published
2023
Full Text
View/download PDF

21. Interleukin‐4 induced 1‐mediated resistance to an immune checkpoint inhibitor through suppression of CD8+ T cell infiltration in melanoma.

Author

Hirose, Shiho, Mashima, Tetsuo, Yuan, Xunmei, Yamashita, Makiko, Kitano, Shigehisa, Torii, Shinichi, Migita, Toshiro, and Seimiya, Hiroyuki

Abstract

Cancer cells adopt multiple strategies to escape tumor surveillance by the host immune system and aberrant amino acid metabolism in the tumor microenvironment suppresses the immune system. Among the amino acid‐metabolizing enzymes is an L‐amino‐acid oxidase called interleukin‐4 induced 1 (IL4I1), which depletes essential amino acids in immune cells and is associated with a poor prognosis in various cancer types. Although IL4I1 is involved in immune metabolism abnormalities, its effect on the therapeutic efficacy of immune checkpoint inhibitors is unknown. In this study, we established murine melanoma cells overexpressing IL4I1 and investigated their effects on the intratumor immune microenvironment and the antitumor efficacy of anti‐programmed death‐ligand 1 (PD‐L1) antibodies (Abs) in a syngeneic mouse model. As a result, we found that IL4I1‐overexpressing B16‐F10‐derived tumors showed resistance to anti‐PD‐L1 Ab therapy. Transcriptome analysis revealed that immunosuppressive genes were globally upregulated in the IL4I1‐overexpressing tumors. Consistently, we showed that IL4I1‐overexpressing tumors exhibited an altered subset of lymphoid cells and particularly significant suppression of cytotoxic T cell infiltration compared to mock‐infected B16‐F10‐derived tumors. After treatment with anti‐PD‐L1 Abs, we also found a more prominent elevation of tumor‐associated macrophage (TAM) marker, CD68, in the IL4I1‐overexpressing tumors than in the mock tumors. Consistently, we confirmed an enhanced TAM infiltration in the IL4I1‐overexpressing tumors and a functional involvement of TAMs in the tumor growth. These observations indicate that IL4I1 reprograms the tumor microenvironment into an immunosuppressive state and thereby confers resistance to anti‐PD‐L1 Abs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Supplementary Table S2 from APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer

Author

Tanaka, Noritaka, primary, Mashima, Tetsuo, primary, Mizutani, Anna, primary, Sato, Ayana, primary, Aoyama, Aki, primary, Gong, Bo, primary, Yoshida, Haruka, primary, Muramatsu, Yukiko, primary, Nakata, Kento, primary, Matsuura, Masaaki, primary, Katayama, Ryohei, primary, Nagayama, Satoshi, primary, Fujita, Naoya, primary, Sugimoto, Yoshikazu, primary, and Seimiya, Hiroyuki, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure S1-S8 from APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer

Author

Tanaka, Noritaka, primary, Mashima, Tetsuo, primary, Mizutani, Anna, primary, Sato, Ayana, primary, Aoyama, Aki, primary, Gong, Bo, primary, Yoshida, Haruka, primary, Muramatsu, Yukiko, primary, Nakata, Kento, primary, Matsuura, Masaaki, primary, Katayama, Ryohei, primary, Nagayama, Satoshi, primary, Fujita, Naoya, primary, Sugimoto, Yoshikazu, primary, and Seimiya, Hiroyuki, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Methods, Figures 1-7, Figure Legends 1-7 from Telomestatin Impairs Glioma Stem Cell Survival and Growth through the Disruption of Telomeric G-Quadruplex and Inhibition of the Proto-oncogene, c-Myb

Author

Miyazaki, Takeshi, primary, Pan, Yang, primary, Joshi, Kaushal, primary, Purohit, Deepti, primary, Hu, Bin, primary, Demir, Habibe, primary, Mazumder, Sarmistha, primary, Okabe, Sachiko, primary, Yamori, Takao, primary, Viapiano, Mariano, primary, Shin-ya, Kazuo, primary, Seimiya, Hiroyuki, primary, and Nakano, Ichiro, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results